Headlines in Reproductive Medicine
June 12, 2013
Progesterone, a female hormone that can be used as a therapy for endometrial cancer, eliminates tumor cells indirectly by binding to its receptor in stromal or connective tissue cells residing in the tumor microenvironment, according to a study from the G.O. Discovery Lab team and collaborators at UCLA.
Headlines in Reproductive Medicine
June 10, 2013
Scientists at the Danish Stem Cell Center, DanStem, at the University of Copenhagen have discovered that they can make embryonic stem cells regress to a stage of development where they are able to make placenta cells as well as the other fetal cells. This significant discovery, published in the journal Cell Reports today, has the potential to shed new light on placenta related disorders that can lead to problematic pregnancies and miscarriages.
Headlines in Reproductive Medicine
June 06, 2013
Emergency contraception known as the "morning-after pill" can be sold over-the-counter to minors, a federal appeals court in New York decided on Wednesday.
Headlines in Reproductive Medicine
June 06, 2013
One of the many ways in which humans' evolved characteristics clash with a fast-changing post-industrial society can be seen in the female egg.
ASRM Bulletins
May 07, 2013
Late Tuesday, FDA approved the application of Teva Women’s Health to allow women 15 and older buy the company’s Plan B One-Step emergency contraceptive pill without prescription.
Press Releases
April 05, 2013
"We are pleased with Judge Korman's decision ordering FDA to lift its restrictions on access to emergency contraceptives. Restricting over-the-counter access by age has historically been a political decision. We agree with the court that these decisions need to be based on science, not politics. In the field of reproductive medicine, politicians too often seek to substitute their judgment for that of physicians and their patients or the scientific evidence. This results in bad medicine and bad policy. Today's decision tells the Federal Government that science should guide policy, and we applaud that stance."
Press Releases
March 20, 2013
An international group of organizations working in women’s health and menopause, including the American Society for Reproductive Medicine (ASRM), met in Paris in November 2012 and undertook a review of clinical guidelines on menopausal hormone therapy (MHT) and the newest research on its safety and disease prevention. In a statement to be published March 15 in the journals, Climacteric and Maturitas, the participants conclude that MHT is the most effective treatment for the symptoms of menopause, but that benefits are more likely to outweigh risks for symptomatic women before the age of 60 or within 10 years after menopause.
ASRM Bulletins
February 28, 2013
Village Fertility Pharmacy is conducting a voluntary recall of
compounded medications shipped over the past three months. The recall
resulted after particulate was discovered in a small percentage of two
lots of Progesterone. Immediately upon learning of the situation,
Village contacted the Massachusetts Board of Pharmacy.
NIH Announcements
January 31, 2013
Last December, the Office of Disease Prevention at the National Institutes of Health (NIH) convened an unbiased, independent panel to assess the available evidence on polycystic ovary syndrome.
ASRM Bulletins
October 29, 2012
It is very important that patients understand what this report does not say: it does not recommend against the use of hormone therapy for the relief of menopausal symptoms.